Continuing with the output of updated clinical guidelines from ENETS, this paper is unlike the others so far in 2022/23/24 where the guidelines were set against several clinical questons for particular scenarios (presumably common in the NET patient population).  So far,the clinical guidelines have centred on Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) (Neuroendocrine Carcinoma (NEC) and Neuroendocrine Tumours (NET)). 

The latest output comes in a different format than the GEP NEN output but is based on Lung NETs, i.e. well differeniated Lung NETs. I’m hoping it is a precurser to a set of updated Lung NEN guidelines.  Although, as you will see there is no well differentiated grade 3 but a special category of well differentiated Lung NET with aggressive features.  The Lung WHO 2021 classification of tumours (see Spotlight on Lung NENs) covered this special category (putting it into the large cell Lung NEC category as a placeholder).  The same reference also failed to remove the ‘carcinoid‘ misnomer word, so my apologies for the use of this term in the attached reference link and in this post. However, still good to see output for Lung NETs.  Worth pointing out that many Lung NEC are handled by Lung Multidiscplinary Teams (MDT), a slightly controversial point, particularly when the statistics for these Neuroendocrine Carcinomas (particulary small cell lung cancer (SCLC) are not inlcuded in overall NEN statistical data. 

The format is based on a survey completed by thirty-four experts from 20 centres specialising in lung NET (I will in due course update my ‘Find a NET expert‘ section to incorporate this useful data).